Src polarizes anti-inflammatory M2 macrophage phenotype and function
详细信息    查看官网全文
摘要
Purpose: Ulcerative colitis, a major inflammatory bowel disease, is an idiopathic inflammatory disorder of the colonic mucosa, accompanied by an aberrant immune reaction to intestinal microflora. Macrophages are central mediators of intestinal immune homeostasis and inflammation. However, the regulation of different phenotypes of macrophages in colitis is poorly understood. Methods: We have administrated Src inhibitor(Dasatinib) in vivo in DSS-induced colitis to investigate the role of Src in regulation of macrophages in colitis. Src inhibitor pretreated BMDMs also have been induced to M1 or M2 macrophags in vitro. Results: Here we showed that Dasatinib treated mice were more susceptible to the DSS-induced colitis, with much more sever inflammation response, more i NOS expression and TNF-α production and at the same time less Arg1 expression and IL-10 production in the colon tissue. What's more, there were more M1 macrophages but less M2 macrophages in the total intestinal macrophages from the colon of the Dasatinib-treated mice after DSS feeding. Mechanistic studies showed that activated Src could inhibit the IFN-γ induced expression of i NOS in BMDM. To the opposite, activated Src could promote the expression of IL-4 induced Arg1 and YM1 expression in BMDM. Further research revealed that Src could positively regulate IL-4-induced activation of Akt and STAT6, which were reported to be necessary for the generation of M2 macrophage phenotype, especially Arg1 expression. However, only overexpression of STAT6 could rescue the inhibition on Arg1 expression by Src inhibitor. Src could associate with STAT6, indicating that Src could activate STAT6. Conclusion: In sum, our results provide the new mechanistic insight to the polarization of M1 and M2 macrophages. Src polarizes anti-inflammatory M2 macrophage phenotype and function through STAT6, indicating the importance of SrcSTAT6 cascade as the target for the design of anti-inflammatory drugs.
Purpose: Ulcerative colitis, a major inflammatory bowel disease, is an idiopathic inflammatory disorder of the colonic mucosa, accompanied by an aberrant immune reaction to intestinal microflora. Macrophages are central mediators of intestinal immune homeostasis and inflammation. However, the regulation of different phenotypes of macrophages in colitis is poorly understood. Methods: We have administrated Src inhibitor(Dasatinib) in vivo in DSS-induced colitis to investigate the role of Src in regulation of macrophages in colitis. Src inhibitor pretreated BMDMs also have been induced to M1 or M2 macrophags in vitro. Results: Here we showed that Dasatinib treated mice were more susceptible to the DSS-induced colitis, with much more sever inflammation response, more i NOS expression and TNF-α production and at the same time less Arg1 expression and IL-10 production in the colon tissue. What's more, there were more M1 macrophages but less M2 macrophages in the total intestinal macrophages from the colon of the Dasatinib-treated mice after DSS feeding. Mechanistic studies showed that activated Src could inhibit the IFN-γ induced expression of i NOS in BMDM. To the opposite, activated Src could promote the expression of IL-4 induced Arg1 and YM1 expression in BMDM. Further research revealed that Src could positively regulate IL-4-induced activation of Akt and STAT6, which were reported to be necessary for the generation of M2 macrophage phenotype, especially Arg1 expression. However, only overexpression of STAT6 could rescue the inhibition on Arg1 expression by Src inhibitor. Src could associate with STAT6, indicating that Src could activate STAT6. Conclusion: In sum, our results provide the new mechanistic insight to the polarization of M1 and M2 macrophages. Src polarizes anti-inflammatory M2 macrophage phenotype and function through STAT6, indicating the importance of SrcSTAT6 cascade as the target for the design of anti-inflammatory drugs.
引文

© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

地址:北京市海淀区学院路29号 邮编:100083

电话:办公室:(+86 10)66554848;文献借阅、咨询服务、科技查新:66554700